

1 **Maternal and child outcomes reported by breastfeeding women following mRNA COVID-**
2 **19 vaccination**

3 Kerri Bertrand¹, Gordon Honerkamp-Smith¹ and Christina Chambers^{1,2}

4 **Affiliations:** Department of Pediatrics¹, and Herbert Wertheim School of Public Health and
5 Longevity Science², University of California, San Diego, La Jolla, CA 92093

6 **Short Title:** Breastfeeding outcomes after COVID-19 vaccination

7 **Address Correspondences to:**

8 Kerri Bertrand
9 Department of Pediatrics
10 University of California, San Diego
11 9500 Gilman Drive, #0828, La Jolla, CA 92093
12 Telephone 858 246 1713
13 Email: kdutcher@health.ucsd.edu
14

15 **Conflict of Interest Disclosures**

16 Dr. Chambers receives research funding from the following industry sponsors and a
17 foundation: Amgen Inc.; AstraZeneca; Celgene; GlaxoSmithKline; Janssen Pharmaceuticals;
18 Pfizer, Inc.; Regeneron; Hoffman La-Roche-Genentech; Genzyme Sanofi-Aventis; Takeda
19 Pharmaceutical Company Limited; Sanofi; UCB Pharma, USA; Sun Pharma Global FZE;
20 Gilead; and the Gerber Foundation.
21

22 **Funding/Support**

23 Funding for this study was in part provided by a supplement to NIH-NICHD R21 Grant Number
24 1R21HD104412-01 to Christina Chambers
25
26

27 **Table of Contents Summary**

28 **What's known on this subject:**

29

30 One published U.S. study with 31 breastfeeding women who were vaccinated with either of the
31 two available mRNA COVID-19 vaccines found that 67% experienced any side effects after
32 dose one and 61% after dose two of the vaccine.

33 **What this study adds:**

34 More than 85% of 180 breastfeeding women who received an mRNA COVID-19 vaccine
35 reported local or systemic symptoms, with higher frequency following the second dose. Few
36 symptoms were reported in their breastfed children. No serious adverse events were noted.

37 **Contributors' Statement Page**

38

39 Dr. Chambers and Ms. Bertrand designed the study and supervised the collection of data used in
40 the study. Mr. Honerkamp-Smith performed the statistical analysis. All authors were involved in
41 preparing the manuscript. All authors approved the final manuscript as submitted and agree to
42 be accountable for all aspects of the work.

43

44 **Acknowledgements**

45

46 The authors wish to thank student researchers Angelique Ghadishah, Bianca Kermani, Samantha
47 Powell, and Zoe Sidiropoulos for helping with data collection. We also wish to express our
48 appreciation to the women who participated in this study for giving so generously of their time
49 and effort to provide clinical information.

50 INTRODUCTION

51 Clinical trials for the both the Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273
52 COVID-19 vaccines demonstrated ability to prevent infection and severe disease, leading to
53 emergency use authorization by the U.S. Food and Drug Administration.^{1, 2}

54 The American College of Obstetrics and Gynecology and The Society for Maternal Fetal
55 Medicine have recommended that these mRNA vaccines be made available for lactating women.
56 However, initial trials excluded breastfeeding women, leading to questions about their safety.³
57 One study of 31 breastfeeding women who received an mRNA vaccine found that >60%
58 reported side effects.⁴ We sought to evaluate a larger sample of vaccinated breastfeeding women
59 and their breastfed children.

60 MATERIALS AND METHODS

61 Breastfeeding women in the U.S. who received an mRNA vaccine were enrolled into the
62 Mommy's Milk Human Milk Research Biorepository at the University of California, San Diego.
63 Demographics, health history, vaccine brand, and maternal symptoms and child events were
64 collected by maternal interview and questionnaire for seven days following each dose. The
65 study was approved by the UC San Diego IRB; written consent was obtained from participants.

66 Maternal and child characteristics and outcomes were compared by brand for each dose
67 using Student's t-test for continuous and Fisher's exact test for categorical variables. Missing
68 values were excluded. R version 25 4.0.3 was used for analyses.

69 Results

70 Between December 14, 2020 and February 1, 2021, 180 women who received either
71 mRNA vaccine were enrolled. As shown in Table 1, 128 women (71.1%) received the Pfizer
72 vaccine and 52 (28.9%) received the Moderna brand. Child age at enrollment averaged 7.47

73 months (SD 5.44, Range 0.09 to 27.45 months). The majority (86.0%) were exclusively
74 breastfed.

75 Following dose one, similar proportions of women reported any vaccine symptom by
76 brand (89.4% Pfizer; 98.1% Moderna); frequency by specific symptom did not differ by brand.
77 However, following dose two, women who received the Moderna brand were significantly more
78 likely to report systemic side effects including chills, muscle/body aches, fever, vomiting. They
79 were also more likely to report localized symptoms including pain, redness, swelling or itching
80 at the injection site than women following dose two of the Pfizer brand (all p's <0.05). A small
81 proportion of women following dose one of either vaccine reported a reduction in milk supply.
82 There was a significant difference in reduction of milk supply following dose two by brand
83 (8.0% vs. 23.4% for Pfizer and Moderna, respectively, p<0.05). However, in all cases milk
84 production returned to normal within 72 hours. Three women reported a change in color of milk
85 (blue-green) following dose one; two reported change in color of milk following dose two (Table
86 2).

87 Few events were reported for children following maternal vaccination with either brand
88 or either dose. The most common child events following dose two were irritability (10.3% and
89 10.4% for Pfizer and Moderna, respectively), poor sleep (7.8% and 8.3% for Pfizer and
90 Moderna respectively), with significantly more drowsiness reported for children whose mothers
91 received Moderna vs. Pfizer (0% vs. 6.4%, p=0.02) (Table 2).

92 **Discussion**

93 We found >85% of participants reported any symptoms for both the Pfizer-BioNTech and
94 Moderna vaccines following either dose. This is substantially higher than the 61-67% of women
95 who reported any symptom in the Gray et al. paper.⁴ This could be due to differences in methods
96 of assessment, timing, and number of symptoms specifically queried. However, consistent with
97 adult participants in clinical trials for each vaccine, we noted increased frequencies of most
98 symptoms following the second dose compared to the first.^{5,6} We also found significantly greater
99 frequencies of localized pain, redness, swelling and itching at the injection site as well as
100 systemic symptoms including chills, muscle/body aches, fever and vomiting following dose two
101 of the Moderna brand vs. Pfizer. Some participants reported a reduction in milk supply, which in
102 all cases returned to normal. We found low frequencies of any events reported in children, all of
103 which were non-serious. To our knowledge there have been no previous studies published on
104 outcomes in breastfed children.

105 These data are reassuring regarding the safety of vaccination in breastfeeding women and
106 their breastfed children with either of the mRNA COVID-19 vaccines. Additional studies are
107 underway to evaluate milk composition and antibody status in samples obtained from women
108 participating in the current study.

References

1. FDA authorizes Pfizer-BioNTech COVID-19 vaccine. *Med Lett Drugs Ther.* Jan 11 2021;63(1615):1-2.
2. FDA authorizes Moderna COVID-19 vaccine. *Med Lett Drugs Ther.* Jan 25 2021;63(1616):9-10.
3. Adhikari EH, Spong CY. COVID-19 Vaccination in Pregnant and Lactating Women. *JAMA.* Mar 16 2021;325(11):1039-1040. doi:10.1001/jama.2021.1658
4. Gray KJ, Bordt EA, Atyeo C, et al. COVID-19 vaccine response in pregnant and lactating women: a cohort study. *Am J Obstet Gynecol.* Mar 24 2021;doi:10.1016/j.ajog.2021.03.023
5. National Center for Immunization and Respiratory Diseases. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine. Updated 12/13/2020. Accessed 04/16, 2021. <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html>
6. National Center for Immunization and Respiratory Diseases. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine. Accessed 04/16, 2021. <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html>

Table 1: Characteristics of breastfeeding women who received either mRNA COVID-19 vaccine and their breastfed children, N=180

	Pfizer/BioNTech n=128	Moderna n= 52	All N= 180
Maternal Age (years)	34.92 (3.67)	34.50 (3.24)	34.80 (3.54)
Race			
White	119 (93.7)	39 (75.0)	159 (88.3)**
Black	0 (0.0)	1 (1.9)	1 (0.6)
Asian	7 (5.5)	12 (23.1)	19 (10.6)
Native American/ Alaska Native	1 (0.8)	0 (0.0)	1 (0.6)
Ethnicity			
Non-Hispanic	123 (96.9)	51 (98.1)	174 (96.7)
Hispanic	4 (3.1)	1 (1.9)	6 (3.3)
Education			
Some College	1 (0.8)	0 (0.0)	1 (0.6)
College Graduate	33 (26.2)	12 (23.5)	45 (25.3)
Post-Graduate	92 (73.0)	39 (76.5)	132 (74.2)
Income per year			
\$10,001-\$49,999	0 (0.0)	1 (2.0)	1 (0.6)
>\$60,000	127 (100.0)	50 (98.0)	178 (99.4)
Full Time Employment	89 (71.8)	34 (66.7)	124 (70.5)
Maternal Co-Morbidities			
BMI >30	16 (12.6)	4 (7.8)	20 (11.2)
Hypertension	2 (1.6)	0 (0.0)	2 (1.1)
Diabetes	0 (0.0)	0 (0.0)	0 (0.0)
Asthma	20 (15.7)	6 (11.5)	26 (14.4)
Prior COVID-19 infection	4 (3.1)	4 (7.7)	8 (4.4)
Child Age in months (SD, Range)	7.60 (5.54, 0.39-27.45)	7.16 (5.26, 0.10-23.45)	7.47 (5.44, 0.09 - 27.45)
Child Sex			
Female	75 (59.5)	25 (49.0)	100 (56.7)
Male	51 (40.5)	26 (51.0)	77 (43.3)
Pre-term Delivery	5 (3.9)	4 (7.7)	9 (5.0)
Exclusive Breastfeeding	107 (84.3)	45 (90.0)	153 (86.0)

*p<0.05 **p<0.005. Continuous variables were summarized by mean (SD) and group comparisons were made using a t-test. Categorical variables were summarized by count (%) and group comparisons were made using Fisher's Exact test.

Table 2. Symptoms reported by breastfeeding women who received either mRNA COVID-19 vaccine and events in their breastfed children

Symptom	Within 7 days of Dose 1				Within 7 days of Dose 2			
	Pfizer-BioNTech		Moderna		Pfizer-BioNTech		Moderna	
	Women n= 126	Children n= 129	Women n= 52	Children n=53	Women n=123	Children n= 126	Women n=52	Children n=53
<i>Any Maternal Symptoms</i>	110 (89.4)		51 (98.1)		114 (98.3)		50 (100.0)	
<i>Any Local Symptoms</i>	105 (86.8)		50 (96.2)		102 (87.9)		48 (98.0)*	
Pain at Injection Site	105 (86.8)		50 (96.2)		102 (87.9)		48 (98.0)	
Redness at Injection Site	7 (5.9)		5 (9.6)		3 (2.6)		15 (31.9)**	
Swelling at Injection Site	7 (5.9)		6 (11.5)		7 (6.1)		14 (29.8)**	
Itching at Injection Site	3 (3.5)		4 (7.7)		5 (4.4)		8 (17.4)*	
<i>Any Systemic Symptoms</i>	51 (41.5)		28 (53.8)		101 (87.1)		48 (96.0)*	
Chills	8 (6.8)		5 (9.6)		55 (47.8)		36 (75.0)**	
Headache	28 (23.7)		13 (25.0)		74 (64.3)		35 (71.4)	
Joint Pain	7 (5.9)		1 (1.9)		31 (27.2)		16 (34.0)	
Muscle/Body Aches	16 (13.6)		6 (11.5)		71 (61.7)		41 (83.7)*	
Fatigue or Tiredness	31 (26.3)		12 (23.1)		82 (71.3)		42 (84.0)	
Fever	1 (0.8)		2 (3.8)		28 (24.3)		23 (46.9)*	
Nausea	5 (4.2)		1 (1.9)		18 (15.7)		13 (27.7)	
Vomiting	0 (0.0)		0 (0.0)		1 (0.9)		4 (8.5)*	
Diarrhea	2 (1.7)		0 (0.0)		3 (2.6)		3 (6.4)	
Abdominal Pain	1 (0.8)		0 (0.0)		4 (3.4)		3 (6.4)	
Rash (body)	1 (0.8)		1 (1.9)		1 (0.9)		1 (2.1)	
Other	7 (5.9)		3 (5.8)		7 (6.3)		3 (6.8)	
<i>Change in Milk Supply</i>								
More Milk	4 (3.3)		0 (0.0)		4 (3.6)		3 (6.4)	
Less Milk	9 (7.3)		6 (11.5)		9 (8.0)		11 (23.4)*	
Change in Milk Color	2 (8.0)		1 (7.1)		1 (4.0)		1 (6.2)	
<i>Child Events</i>								
Drowsiness		0 (0.0)		1 (2.0)		0 (0.0)		3 (6.4)*
Sedation		0 (0.0)		0 (0.0)		0 (0.0)		0 (0.0)
Poor feeding		0 (0.0)		0 (0.0)		0 (0.0)		1 (2.1)
Rash		1 (0.8)		0 (0.0)		1 (0.9)		1 (2.1)
Bruising/bleeding		0 (0.0)		0 (0.0)		0 (0.0)		0 (0.0)
Constipation		0 (0.0)		1 (2.0)		1 (0.9)		1 (2.1)
Diarrhea		1 (0.8)		2 (3.9)		3 (2.6)		1 (2.1)
Stools w/ abnormal color		1 (0.8)		2 (3.9)		2 (1.7)		2 (4.2)
Fever		2 (1.7)		0 (0.0)		2 (1.7)		0 (0.0)
Low Body Temp		0 (0.0)		0 (0.0)		0 (0.0)		0 (0.0)
Restlessness		1 (0.8)		0 (0.0)		4 (3.4)		2 (4.2)
Irritability		2 (1.7)		2 (3.9)		12 (10.3)		5 (10.4)
Poor sleep		4 (3.4)		3 (5.9)		9 (7.8)		4 (8.3)
High-pitched crying		0 (0.0)		0 (0.0)		0 (0.0)		0 (0.0)
Abnormal movements		0 (0.0)		0 (0.0)		0 (0.0)		0 (0.0)
Abnormal skin color		1 (0.8)		0 (0.0)		0 (0.0)		0 (0.0)

*p<0.05 **p<0.005. Variables were summarized by count (%) and group comparisons were made using Fisher's Exact test.